CVS Health To Reaffirm FY23 Adjusted EPS Guidance Range Of $8.50-$8.70; Est $8.59
Portfolio Pulse from Benzinga Newsdesk
CVS Health's senior management team will meet with investors on September 12, 2023, to reaffirm the company's previously announced full year 2023 GAAP diluted earnings per share guidance range of $6.53 to $6.75, and its full year 2023 cash flow from operations guidance range of $12.5 billion to $13.5 billion.
September 11, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CVS Health is reaffirming its FY23 GAAP diluted EPS guidance and cash flow from operations guidance. This reaffirmation could provide stability and confidence to investors.
Reaffirming guidance is generally a positive sign as it indicates that the company is confident in its ability to meet its financial targets. However, since this is a reaffirmation and not an increase, the impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100